mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro

Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy

(2017) Daniel Kraus et al.   MOLECULAR CANCER THERAPEUTICS

Type I and Type II Photosensitized Oxidation Reactions: Guidelines and Mechanistic Pathways

(2017) Maurício S. Baptista et al.   PHOTOCHEMISTRY AND PHOTOBIOLOGY

ALA-PDT suppressing the cell growth and reducing the lipogenesis in human SZ95 sebocytes by mTOR signaling pathway in vitro

(2017) Jiang Tuo et al.   Photodiagnosis and Photodynamic Therapy

Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions

(2017) Demian van Straten et al.   Cancers

Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.

(2017) H. Mackay et al.   JOURNAL OF CLINICAL ONCOLOGY

Current Treatment of Metastatic Endometrial Cancer

(2017) Sarah M. Temkin et al.   Cancer Control

New photosensitizers for photodynamic therapy

(2016) H. Abrahamse et al.   BIOCHEMICAL JOURNAL

New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation

(2016) Matthias Waldner et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

(2016) David R. Driscoll et al.   CANCER RESEARCH

The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging

(2016) Brian K. Kennedy et al.   Cell Metabolism

Structural insights of mTOR complex 1

(2016) Hai-Xin Yuan et al.   CELL RESEARCH

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

(2016) James C Yao et al.   LANCET

Metabolic maintenance of cell asymmetry following division in activated T lymphocytes

(2016) Katherine C. Verbist et al.   NATURE

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

(2016) Vanessa S. Rodrik-Outmezguine et al.   NATURE

mTORC1 and mTORC2 in cancer and the tumor microenvironment

(2016) L C Kim et al.   ONCOGENE

Management of side effects of mTOR inhibitors in tuberous sclerosis patients

(2016) Krzysztof Sadowski et al.   Pharmacological Reports

mTOR inhibitors in urinary bladder cancer

(2016) R. Pinto-Leite et al.   TUMOR BIOLOGY

Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?

(2016) Samy L Habib et al.   Journal of Cancer

Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor

(2015) Babasola Fateye et al.   Photodiagnosis and Photodynamic Therapy

Architecture of human mTOR complex 1

(2015) C. H. S. Aylett et al.   SCIENCE

Current treatment strategies for inhibiting mTOR in cancer

(2015) Francesca Chiarini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades

(2015) James Andrew McCubrey et al.   Oncotarget

Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities

(2014) Tan Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Fabrice André et al.   LANCET ONCOLOGY

Making new contacts: the mTOR network in metabolism and signalling crosstalk

(2014) Mitsugu Shimobayashi et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo

(2014) Temitope Sasore et al.   PLoS One

Photodynamic Therapy and Its Role in Combined Modality Anticancer Treatment

(2014) N. Patrik Brodin et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

(2014) B. C. Grabiner et al.   Cancer Discovery

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

(2014) N. Wagle et al.   Cancer Discovery

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

(2013) Sara A. Hurvitz et al.   BREAST CANCER RESEARCH AND TREATMENT

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial

(2013) Howard A. Burris et al.   CANCER

Targeting the mTOR Pathway in Tumor Malignancy

(2013) Hengmiao Cheng et al.   CURRENT CANCER DRUG TARGETS

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

(2013) A.V. Tinker et al.   GYNECOLOGIC ONCOLOGY

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Synergistic effect of radachlorin mediated photodynamic therapy on propolis induced apoptosis in AMC-HN-4 cell lines via caspase dependent pathway

(2013) Jin-Chul Ahn et al.   Photodiagnosis and Photodynamic Therapy

The Paradox of Akt-mTOR Interactions

(2013) Lakshmipathi Vadlakonda et al.   Frontiers in Oncology

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells

(2012) Benjamin Blaser et al.   BMC CANCER

mTOR inhibitors in cancer therapy

(2012) Yekaterina Y. Zaytseva et al.   CANCER LETTERS

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

mTOR Signaling in Cancer Cell Motility and Tumor Metastasis

(2012) Hongyu Zhou et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Targeting the PI3K signaling pathway in cancer therapy

(2012) Chandra Bartholomeusz et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy

(2012) Alejandro Gomez-Pinillos et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

The mTOR Signalling Pathway in Human Cancer

(2012) Helena Pópulo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: Synthesis, preparation and in vivo evaluation

(2012) Pengcheng Zhang et al.   JOURNAL OF CONTROLLED RELEASE

Combination of Phosphatidylinositol 3-Kinases Pathway Inhibitor and Photodynamic Therapy in Endothelial and Tumor Cells

(2012) Babasola Fateye et al.   PHOTOCHEMISTRY AND PHOTOBIOLOGY

PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies

(2012) Lise Willems et al.   Current Oncology Reports

Circumventing Cancer Drug Resistance in the Era of Personalized Medicine

(2012) Levi A. Garraway et al.   Cancer Discovery

Photodynamic therapy of cancer: An update

(2011) Patrizia Agostinis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

(2011) Jaume Capdevila et al.   CANCER AND METASTASIS REVIEWS

mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways

(2011) P. Gulhati et al.   CANCER RESEARCH

Decreased Lymphangiogenesis and Lymph Node Metastasis by mTOR Inhibition in Head and Neck Cancer

(2011) V. Patel et al.   CANCER RESEARCH

mTOR complex 2 signaling and functions

(2011) Won Jun Oh et al.   CELL CYCLE

An emerging role for TOR signaling in mammalian tissue and stem cell physiology

(2011) Ryan C. Russell et al.   DEVELOPMENT

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

(2011) Yan-Jie Zhang et al.   DRUG DISCOVERY TODAY

RNA interference targeting raptor inhibits proliferation of gastric cancer cells

(2011) William Ka Kei Wu et al.   EXPERIMENTAL CELL RESEARCH

Activating mutations of TOR (target of rapamycin)

(2011) Molly Hardt et al.   GENES TO CELLS

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

(2011) Kian Behbakht et al.   GYNECOLOGIC ONCOLOGY

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2

(2011) Greg M Delgoffe et al.   NATURE IMMUNOLOGY

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of mTORC1 Signaling by pH

(2011) Aruna D. Balgi et al.   PLoS One

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

(2011) Q. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

(2011) Yesid Alvarado et al.   Targeted Oncology

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

(2010) D. C. Cho et al.   CLINICAL CANCER RESEARCH

Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity

(2010) Lei Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo

(2010) Didier Roulin et al.   Molecular Cancer

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Rapamycin inhibits mTORC1, but not completely

(2009) Carson C. Thoreen et al.   Autophagy

Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles

(2009) Cheng-Liang Peng et al.   BIOMATERIALS

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary

(2009) S. Mabuchi et al.   CLINICAL CANCER RESEARCH

Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer

(2009) P. Gulhati et al.   CLINICAL CANCER RESEARCH

Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis

(2009) Aaron Shafer et al.   INTERNATIONAL JOURNAL OF CANCER

Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells

(2009) Ho-Kee Koon et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Targeting the mTOR Signaling Network for Cancer Therapy

(2009) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Oncogene Addiction

(2008) I. B. Weinstein et al.   CANCER RESEARCH

Mediobasal Hypothalamic p70 S6 Kinase 1 Modulates the Control of Energy Homeostasis

(2008) Clémence Blouet et al.   Cell Metabolism

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Photodynamic Therapy Targets the mTOR Signaling Networkin Vitroandin Vivo

(2008) Anette Weyergang et al.   MOLECULAR PHARMACEUTICS

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE